Jean-François Millau
CEO
TATUM bioscience
The startup develops synthetic live biotherapeutic drugs that utilize engineered probiotics to provide targeted therapeutic activities against diseases resistant to conventional treatments. By addressing bacterial resistance and enhancing treatment efficacy, the company enables healthcare providers to offer effective solutions for conditions that traditional pharmaceuticals cannot manage.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$330KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops synthetic live biotherapeutic drugs that utilize engineered probiotics to provide targeted therapeutic activities against diseases resistant to conventional treatments. By addressing bacterial resistance and enhancing treatment efficacy, the company enables healthcare providers to offer effective solutions for conditions that traditional pharmaceuticals cannot manage.